Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells - Wikidata - awgldk - TriplyDB

Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells

Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells

http://www.wikidata.org/entity/Q42114592

about

Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth Myeloid-derived suppressor cells: linking inflammation and cancer Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment Myeloid suppressor cells and immune modulation in lung cancer Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer.Enhancing cellular cancer vaccines Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells.A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality.Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy Myeloid-derived suppressor cells: paradoxical roles in infection and immunity.PEITC treatment suppresses myeloid derived tumor suppressor cells to inhibit breast tumor growth.Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80 Myeloid derived suppressor cells in human diseases Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer Identification of CD4(+)CD25(+)CD127(-) regulatory T cells and CD14(+)HLA(-)DR(-)/low myeloid-derived suppressor cells and their roles in the prognosis of breast cancer Detection of immune suppressive neutrophils in peripheral blood samples of cancer patients.Modulating the expression of IFN regulatory factor 8 alters the protumorigenic behavior of CD11b+Gr-1+ myeloid cells.Mechanisms of T-cell inhibition: implications for cancer immunotherapy.Influence of human immune cells on cancer: studies at the University of Colorado.Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function.Cross-talk between tumor and myeloid cells: how to tip the balance in favor of antitumor immunity.Myeloid-derived suppressor cells: a double-edged sword?Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients.Amino acid metabolism related to immune tolerance by MDSCs.Myeloid-derived suppressor cells (MDSCs) in gliomas and glioma-development.Phenotypic plasticity of MDSC in cancers.Highlights on molecular mechanisms of MDSC-mediated immune suppression: paving the way for new working hypotheses.Myeloid-derived suppressor cells in cancer: recent progress and prospects.Signaling pathways involved in MDSC regulation.Myeloid-derived suppressor cell heterogeneity in human cancers.CD33(+) /HLA-DR(neg) and CD33(+) /HLA-DR(+/-) Cells: Rare Populations in the Human Decidua with Characteristics of MDSC.Highlights on mechanisms of drugs targeting MDSCs: providing a novel perspective on cancer treatment.Myeloid-Derived Suppressor Cells and Therapeutic Strategies in Cancer.The immunobiology of myeloid-derived suppressor cells in cancer.

P2860

Q21560837-882E3974-35AA-4A2E-997A-9D769FC19C12 Q24641811-7DEF01E1-C357-4EB8-A962-82CEF6D3F028 Q26799126-A7AB3325-EAD7-42B4-A038-F0F9EE1E0D37 Q26823251-71BD8C1F-1D29-4EAF-B9FF-0F53457601AA Q27027064-8F5E2BD8-E355-41C6-826E-6F18AA8B6B4C Q30413623-C7AE3434-223E-4D73-BDB1-7E6C643EE0A3 Q33547396-0ED0C0BA-5E11-42D7-B609-B91DD0C75F2B Q33604925-AE52C03A-3CD6-42E9-95D7-F5BBF49DC440 Q34044797-0BD62AD5-E554-4DBE-BD1B-6CF4BC6ACA9F Q34161849-ED1309BA-5A35-4783-A92A-8C18B209F9E5 Q34570094-3E3C79B4-E674-413D-8F7A-C736F914B713 Q34648541-CC65DBEC-B658-4290-84B7-EDC69F599BD9 Q34810257-2876D01D-3951-4B7C-B8C5-A860C8EFBF91 Q35143001-F7E4E416-D158-400B-86ED-636EC9A1AC0D Q35506493-D6B31BF0-3D75-43CD-8B8E-91767E8DF169 Q36039709-2BB0B042-B5B5-47FB-8B75-F2ACB216C034 Q36338349-6789EAEC-6FDF-4C58-A6C9-0F363D61D766 Q36386903-A377DD2D-0D11-44DD-ACAB-122C25B807F8 Q36821572-EBB70591-3BAA-40D2-8E04-DB0F1A46E8FE Q36981510-F8194AF6-39E6-4C23-8217-AACD3AAB6CC6 Q37108235-2AD8729A-F8ED-4A91-AC5C-9FF1E519E94C Q37127538-A7D535C2-2FD4-4DF4-AFFD-8746BBE2151A Q37347953-F5D6622A-C8E3-427A-A2B3-DE95E8AE5B8F Q37658886-7FCC7FCB-EDE4-42C4-9469-4C3FCAC58537 Q37698684-33E00D43-EC79-4D68-B4B9-F6913F1D5F03 Q37808561-34E7B816-A6C2-4BD1-BE20-E15CC6102BA4 Q37822746-B3D5F677-4AF4-4011-A834-91E6A90B69F9 Q37840240-22B55B0A-B216-4DD6-8483-EBD058E98477 Q37961577-E7412DC4-FDD5-48CC-B0F1-D4530305A90D Q38010200-38DB4DF5-1718-41D2-9255-042E4CD65C96 Q38047053-EF45A558-59FB-4E6D-B87B-8D241A5165FA Q38047054-D70245F6-2A86-4A6D-B43D-75681B29B81A Q38047056-43D18B82-8E97-42D3-94A9-764EB071D1EB Q38116711-37B60209-317B-4008-BA26-0E3A9C52C83C Q38204175-F52A34D0-02B0-425B-8D3F-AA3709FC6323 Q38223250-35F1ABBF-ED52-43CA-82E4-883660E35035 Q38294011-235AE3BD-C78C-4FD0-AA8B-564A91DACAD4 Q38398117-24348A00-7DC1-4AC3-82B0-165A5456BBF4 Q38528814-7BE51EA3-5B9E-433F-AC1E-F0D4AE4EB6EC Q38649547-DB93BF11-6C46-40D9-998D-E4A1C6F9B03F

P2860

Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells

http://www.wikidata.org/entity/Q42114592

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Lung cancer patients' CD4

@nl

Lung cancer patients' CD4(+) T ...... eloid-derived suppressor cells

@en

type

label

Lung cancer patients' CD4

@nl

Lung cancer patients' CD4(+) T ...... eloid-derived suppressor cells

@en

prefLabel

Lung cancer patients' CD4

@nl

Lung cancer patients' CD4(+) T ...... eloid-derived suppressor cells

@en

P1433

Q42114592-FA07CEC8-36B9-48D0-9924-1C98A2DE5D0A

P1476

Q42114592-5FD14537-A4A5-4C65-9513-D4F0F815AEC9

P2093

Q42114592-57613C70-A788-4C1C-8401-219692363582

Q42114592-6E791A22-F5C1-4FCF-AF76-C5D3E1530035

Q42114592-A27FEFC4-B272-4B9D-AEFD-7C18E2BDEFC1

Q42114592-CF9B3DAD-3E2F-4912-B7EE-D82B828933EC

Q42114592-F69E5039-93E8-436E-9819-7C730AD47C64

P2860

Q42114592-02D8EAD1-C226-40C8-BED9-D8D667ECFB42

Q42114592-06A7205F-793F-44E6-AE5D-01679D23E94A

Q42114592-0991B8C5-67EC-444F-AD7C-025EB0579485

Q42114592-0AF74758-0045-442D-829D-48056B4C3ADB

Q42114592-1AE11497-7541-4F02-A160-298D5B70C401

Q42114592-21C04116-E48A-4F40-8D8D-6B802FD82B71

Q42114592-24DCDCB8-2A10-4485-86C8-691BB338B858

Q42114592-26F2512C-1ECE-445D-878C-B47D224B360B

Q42114592-371A1464-D1F0-4DC1-9A2E-8F1B709BE5E6

Q42114592-47C8FC97-CDF9-4149-9790-41F7A409E7C7

P2888

Q42114592-2FF08A7C-17E0-4C4C-8F17-5F457AA3AB22

P304

Q42114592-9E694F90-1534-41CC-9491-5B5420357B65

P31

Q42114592-8A43C7CB-17FA-4638-A2EB-F2473B2CFF57

P356

Q42114592-7CDC7819-093B-4E58-B486-55BC8C803206

P433

Q42114592-920513D2-2A54-41C3-8752-B1251AE1C3D1

P478

Q42114592-86B66402-DD2C-4371-9857-3B0E7B2338A7

P50

Q42114592-DED8498B-0E24-4C22-8B4C-BB017EC0C5E3

P577

Q42114592-E6580466-A94B-4B1A-8183-1970B15E1E2E

P5875

Q42114592-BB43D637-98B9-4B26-8398-96FF717D54D3

P6179

Q42114592-74A72307-D6D2-45FC-B06A-F2BB37E4B943

P698

Q42114592-D99D4A70-50D6-4C2D-8EB9-293CC7149B7B

P932

Q42114592-52CAE0AA-8F96-4CAC-A9A1-6A519119F949

P356

S00262-008-0490-9

P1433

Cancer Immunology, Immunotherapy

P1476

Lung cancer patients' CD4(+) T ...... eloid-derived suppressor cells

@en

P2093

Bruce R Ksander

http://www.w3.org/2001/XMLSchema#string

James A Thompson

http://www.w3.org/2001/XMLSchema#string

Martin J Edelman

http://www.w3.org/2001/XMLSchema#string

Minu K Srivastava

http://www.w3.org/2001/XMLSchema#string

Suzanne Ostrand-Rosenberg

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation of immune responses by TGF-beta

Cancer statistics, 2007

Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers.

Chemotherapy for advanced non-small-cell lung cancer: modest progress, many choices.

Requirement for CD4 T cell help in generating functional CD8 T cell memory.

Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.

Immature myeloid cells and cancer-associated immune suppression.

Cancer vaccines: between the idea and the reality.

Derangement of immune responses by myeloid suppressor cells.

Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells

P2888

s00262-008-0490-9

P304

1493-1504

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-008-0490-9

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P50

Jacobus J Bosch

P577

2008-03-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5529037

http://www.w3.org/2001/XMLSchema#string

P6179

1028262962

http://www.w3.org/2001/XMLSchema#string

P698

18322683

http://www.w3.org/2001/XMLSchema#string

P932

2805175

http://www.w3.org/2001/XMLSchema#string